Dapagliflozin crystalline form and preparation method thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9550747
APP PUB NO 20160347731A1
SERIAL NO

15117533

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a new crystalline form of dapagliflozin represented by formula (I). The crystalline form has a characteristic absorption peak at about 4.318 (20.45) in an X-ray powder diffraction pattern shown by angle 2 theta and interplanar spacing (value d). It can be prepared by dissolving dapagliflozin in good organic solvents, adding poor solvents, stirring to crystallization, filtering and drying. The new crystalline form of dapagliflozin of the present invention has the following superior features: good solubility, low hygroscopicity, high stability and good preparation reproducibility.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTDECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE LIANYUNGANG 222069

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Li, Xiaobi Jiangsu, CN 1 5
Yuan, Fuping Jiangsu, CN 1 5
Zhang, Tiancheng Jiangsu, CN 3 5
Zhu, Xifeng Jiangsu, CN 3 6

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 24, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00